Provided by Tiger Trade Technology Pte. Ltd.

SPYRE THERAPEUTICS INC

86.53
-1.9700-2.23%
Volume:974.52K
Turnover:84.56M
Market Cap:7.63B
PE:-43.05
High:90.18
Open:88.05
Low:85.00
Close:88.50
52wk High:110.18
52wk Low:14.51
Shares:88.17M
Float Shares:80.98M
Volume Ratio:0.57
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0100
EPS(LYR):-1.9755
ROE:-22.98%
ROA:-19.81%
PB:7.99
PE(LYR):-43.80

Loading ...

Analysts Offer Insights on Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Spyre Therapeutics (SYRE) and Henry Schein (HSIC)

TIPRANKS
·
Mar 31

Stifel Nicolaus Remains a Buy on Spyre Therapeutics (SYRE)

TIPRANKS
·
Mar 23

Spyre Therapeutics (SYRE) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Mar 21

Spyre Therapeutics Completes First-in-Human Study of SPY001-001, De-risking Early Pipeline

TIPRANKS
·
Mar 21

Spyre Therapeutics (SYRE) Valuation After Accelerated SKYWAY Trial Timeline And Rising Investor Interest

Simply Wall St.
·
Mar 19

Spyre Therapeutics (SYRE) Is Up 7.3% After Accelerating SPY072 Phase 2 POC Timeline - Has The Bull Case Changed?

Simply Wall St.
·
Mar 17

Analysts’ Top Healthcare Picks: Oneview Healthcare Chess Depository Interests repr 1 (ONVVF), Spyre Therapeutics (SYRE)

TIPRANKS
·
Mar 17

Spyre Therapeutics completes recruitment for SKYWAY basket trial sub-study

TIPRANKS
·
Mar 16

BRIEF-Spyre Announces Acceleration Of Expected Topline Readout Of Skyway Rheumatoid Arthritis Sub-Study To Q3 2026

Reuters
·
Mar 16

Spyre Therapeutics Inc - Skyline Uc Trial Enrolling Ahead of Schedule; Part a Readouts Begin Q2 2026

THOMSON REUTERS
·
Mar 16

Spyre Therapeutics Inc - Psa and Axspa Sub-Study Recruitment on Track; Topline Data Expected Q4 2026

THOMSON REUTERS
·
Mar 16

Spyre Therapeutics Grants Inducement Stock Options for 46,600 Shares

Reuters
·
Mar 07

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire
·
Mar 07

Spyre Therapeutics CFO Scott L Burrows Disposes of Common Shares

Reuters
·
Mar 04

Spyre Therapeutics CEO Cameron Turtle Disposes of Common Shares

Reuters
·
Mar 04